Treatment of More Than Moderate Ischemic Mitral Regurgitation in Patients Undergoing Left Ventricular Reconstruction

Objective:. While evidence-based clinical guidelines recommend chordal-sparing mitral valve replacement, rather than mitral valve repair, in patients with severe ischemic mitral regurgitation (IMR) undergoing coronary artery bypass grafting, there are no similar recommendations for patients undergoi...

Full description

Saved in:
Bibliographic Details
Main Authors: Xieraili Tiemuerniyazi, Yangwu Song, Hanping Ma, Fei Xu, Wei Zhao
Format: Article
Language:English
Published: Wolters Kluwer Health/LWW 2023-03-01
Series:Cardiology Discovery
Online Access:http://journals.lww.com/10.1097/CD9.0000000000000072
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850265788279160832
author Xieraili Tiemuerniyazi
Yangwu Song
Hanping Ma
Fei Xu
Wei Zhao
author_facet Xieraili Tiemuerniyazi
Yangwu Song
Hanping Ma
Fei Xu
Wei Zhao
author_sort Xieraili Tiemuerniyazi
collection DOAJ
description Objective:. While evidence-based clinical guidelines recommend chordal-sparing mitral valve replacement, rather than mitral valve repair, in patients with severe ischemic mitral regurgitation (IMR) undergoing coronary artery bypass grafting, there are no similar recommendations for patients undergoing left ventricular reconstruction (LVR). This study aimed to compare the clinical outcomes of mitral valve repair and replacement in patients undergoing LVR complicated by more than moderate IMR. Methods:. In this single-center cohort study, a total of 74 consecutive patients who underwent LVR and mitral valve surgery (repair group: 59; replacement group: 15), during the period from March 2000 to March 2021 at Fuwai Hospital (Beijing, China) were retrospectively enrolled. Survival rates were calculated with the Kaplan-Meier method and compared using the log-rank test. Univariate Cox analysis was performed to evaluate possible confounders, followed by adjustment in multivariate analysis. The primary outcome was survival free of major adverse cardiovascular and cerebrovascular events (MACCE). Results:. Median follow-up time was 59.4 months. Compared with mitral valve replacement, mitral valve repair was associated with increased risk of perioperative use of ventricular assist device (22.0% vs. 0, P = 0.045). There was no difference in overall survival (hazard ratio (HR), 1.10; 95% confidence interval (CI), 0.31–3.93; Plogrank = 0.888) and MACCE-free survival (HR, 1.54; 95% CI, 0.65–3.65; Plogrank = 0.319), even after multivariate Cox regression (HR, 1.35; 95% CI, 0.37–4.88; PCox = 0.646; and HR, 1.41; 95% CI, 0.57–3.44; PCox = 0.455, respectively). Furthermore, while no differences were observed in ejection fraction and left ventricular end-diastolic diameter on follow-up echocardiography, mitral valve repair was associated with an increased risk of recurrent mitral regurgitation (P = 0.041). Conclusions:. In patients undergoing LVR complicated by more than moderate IMR, both concomitant mitral valve repair and replacement can be successfully achieved with comparable overall and MACCE-free survival outcomes; however, mitral valve replacement may be superior to mitral valve repair for persistent correction of mitral dysfunction.
format Article
id doaj-art-8eb7740f5556414d8ebab19a4d9de7b4
institution OA Journals
issn 2096-952X
2693-8499
language English
publishDate 2023-03-01
publisher Wolters Kluwer Health/LWW
record_format Article
series Cardiology Discovery
spelling doaj-art-8eb7740f5556414d8ebab19a4d9de7b42025-08-20T01:54:19ZengWolters Kluwer Health/LWWCardiology Discovery2096-952X2693-84992023-03-0131162310.1097/CD9.0000000000000072202303000-00003Treatment of More Than Moderate Ischemic Mitral Regurgitation in Patients Undergoing Left Ventricular ReconstructionXieraili Tiemuerniyazi0Yangwu Song1Hanping Ma2Fei Xu3Wei Zhao4Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.Objective:. While evidence-based clinical guidelines recommend chordal-sparing mitral valve replacement, rather than mitral valve repair, in patients with severe ischemic mitral regurgitation (IMR) undergoing coronary artery bypass grafting, there are no similar recommendations for patients undergoing left ventricular reconstruction (LVR). This study aimed to compare the clinical outcomes of mitral valve repair and replacement in patients undergoing LVR complicated by more than moderate IMR. Methods:. In this single-center cohort study, a total of 74 consecutive patients who underwent LVR and mitral valve surgery (repair group: 59; replacement group: 15), during the period from March 2000 to March 2021 at Fuwai Hospital (Beijing, China) were retrospectively enrolled. Survival rates were calculated with the Kaplan-Meier method and compared using the log-rank test. Univariate Cox analysis was performed to evaluate possible confounders, followed by adjustment in multivariate analysis. The primary outcome was survival free of major adverse cardiovascular and cerebrovascular events (MACCE). Results:. Median follow-up time was 59.4 months. Compared with mitral valve replacement, mitral valve repair was associated with increased risk of perioperative use of ventricular assist device (22.0% vs. 0, P = 0.045). There was no difference in overall survival (hazard ratio (HR), 1.10; 95% confidence interval (CI), 0.31–3.93; Plogrank = 0.888) and MACCE-free survival (HR, 1.54; 95% CI, 0.65–3.65; Plogrank = 0.319), even after multivariate Cox regression (HR, 1.35; 95% CI, 0.37–4.88; PCox = 0.646; and HR, 1.41; 95% CI, 0.57–3.44; PCox = 0.455, respectively). Furthermore, while no differences were observed in ejection fraction and left ventricular end-diastolic diameter on follow-up echocardiography, mitral valve repair was associated with an increased risk of recurrent mitral regurgitation (P = 0.041). Conclusions:. In patients undergoing LVR complicated by more than moderate IMR, both concomitant mitral valve repair and replacement can be successfully achieved with comparable overall and MACCE-free survival outcomes; however, mitral valve replacement may be superior to mitral valve repair for persistent correction of mitral dysfunction.http://journals.lww.com/10.1097/CD9.0000000000000072
spellingShingle Xieraili Tiemuerniyazi
Yangwu Song
Hanping Ma
Fei Xu
Wei Zhao
Treatment of More Than Moderate Ischemic Mitral Regurgitation in Patients Undergoing Left Ventricular Reconstruction
Cardiology Discovery
title Treatment of More Than Moderate Ischemic Mitral Regurgitation in Patients Undergoing Left Ventricular Reconstruction
title_full Treatment of More Than Moderate Ischemic Mitral Regurgitation in Patients Undergoing Left Ventricular Reconstruction
title_fullStr Treatment of More Than Moderate Ischemic Mitral Regurgitation in Patients Undergoing Left Ventricular Reconstruction
title_full_unstemmed Treatment of More Than Moderate Ischemic Mitral Regurgitation in Patients Undergoing Left Ventricular Reconstruction
title_short Treatment of More Than Moderate Ischemic Mitral Regurgitation in Patients Undergoing Left Ventricular Reconstruction
title_sort treatment of more than moderate ischemic mitral regurgitation in patients undergoing left ventricular reconstruction
url http://journals.lww.com/10.1097/CD9.0000000000000072
work_keys_str_mv AT xierailitiemuerniyazi treatmentofmorethanmoderateischemicmitralregurgitationinpatientsundergoingleftventricularreconstruction
AT yangwusong treatmentofmorethanmoderateischemicmitralregurgitationinpatientsundergoingleftventricularreconstruction
AT hanpingma treatmentofmorethanmoderateischemicmitralregurgitationinpatientsundergoingleftventricularreconstruction
AT feixu treatmentofmorethanmoderateischemicmitralregurgitationinpatientsundergoingleftventricularreconstruction
AT weizhao treatmentofmorethanmoderateischemicmitralregurgitationinpatientsundergoingleftventricularreconstruction